Why Genmab Still Deserves a Buy: Phase-3 Optionality, M&A Accretion and a Reasonable Valuation
Genmab trades at $26.83 with a $17.3B market cap, a mid-teens P/E and active pipeline catalysts including a Phase 3 advancement that expands clinical optionality. We maintain Buy with a mid-term trade plan: entry $26.83, target $33.00, stop $24.00 (45 trading days). Risk/reward favors a constructive stance given recent deal activity, topline Phase …